Cargando…
A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers
Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analy...
Autores principales: | Han, Yang, Lu, Su, Yu, Fudong, Liu, Xisheng, Sun, Huimin, Wang, Jingtao, Zhu, Xingwu, Lu, Huijun, Yue, Hao, Wang, Jing, Lin, Jun, Zhou, Chongzhi, Tang, Huamei, Peng, Zhihai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109035/ https://www.ncbi.nlm.nih.gov/pubmed/27845412 http://dx.doi.org/10.1038/srep37240 |
Ejemplares similares
-
PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy
por: Chen, Jian, et al.
Publicado: (2014) -
Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer
por: Zhang, Yu, et al.
Publicado: (2015) -
Metalloproteases meprin-ɑ (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer
por: Wang, Xiao, et al.
Publicado: (2016) -
Correction to: Metalloproteases meprin-ɑ (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer
por: Wang, Xiao, et al.
Publicado: (2018) -
Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer
por: Wang, Jingtao, et al.
Publicado: (2015)